Search
Beyond Air Inc
XAIRAdd to Watchlist
0.468USD
+0.001+0.30%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
5.52MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.30%
5 Days
-5.45%
1 Month
+3.98%
6 Months
-40.68%
Year to Date
-35.54%
1 Year
-86.93%
Key Figures
0.463Open
0.480High
185.61KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.57%Turnover Ratio
0.467Prev. Close
0.436Low
66.08KTurnover
LossP/E Static
0.90P/B
0.00%Div Yield TTM
-90.33%ROA
5.84252wk High
0.74Volume Ratio
-46.63MNet Profit
11.79MShares
-4.4418EPS TTM
0.57Beta
-240.75%ROE
0.66752wk Low
9.30%Amplitude
4.93%Gross Margin
5.52MMarket Cap
0.63Reward/Risk
5.78%Risk Rate
TradingKey Stock Score of Beyond Air Inc
Currency: USD Updated: 2026-07-02Key Insights
Beyond Air Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 135 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Beyond Air Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Beyond Air Inc Highlights
StrengthsRisks
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 562.55% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 7.68M.
Undervalued
The company’s latest PE is -0.11, at a low 3-year percentile range.
Analyst Rating
Based on
3
analysts
Buy
Current Rating
7.000
Target Price
+1400.21%
Upside Space
Beyond Air Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Beyond Air Inc Info
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. Its segments include Beyond Air, Beyond Cancer, and NeuroNos. It has received United States Food and Drug Administration approval for its first system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. The Company is advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19) and nontuberculous mycobacteria. It has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder and other neurological disorders. Its product pipeline includes LungFit PH, LungFit PRO, LungFit GO, and others.
Ticker SymbolXAIR
CompanyBeyond Air Inc
CEOLisi (Steven A)
Websitehttps://www.beyondair.net/
Related Instruments
-0.37%
+1.91%
+3.48%
+5.87%
+2.10%
-0.10%
+4.19%
+5.03%
+4.30%
+0.25%
+3.65%
+4.74%
+2.79%
+2.59%
-3.06%
+3.40%
+3.76%
+1.10%
+0.28%
-2.09%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of Beyond Air Inc (XAIR)?
The current price of Beyond Air Inc (XAIR) is 0.47.
What is the symbol of Beyond Air Inc?
The ticker symbol of Beyond Air Inc is XAIR.
What is the 52-week high of Beyond Air Inc?
The 52-week high of Beyond Air Inc is 5.84.
What is the 52-week low of Beyond Air Inc?
The 52-week low of Beyond Air Inc is 0.67.
What is the market capitalization of Beyond Air Inc?
The market capitalization of Beyond Air Inc is 5.52M.
Is Beyond Air Inc (XAIR) currently rated as Buy, Hold, or Sell?
According to analysts, Beyond Air Inc (XAIR) has an overall rating of Buy, with a price target of 7.00.
What is the Earnings Per Share (EPS TTM) of Beyond Air Inc (XAIR)?
The Earnings Per Share (EPS TTM) of Beyond Air Inc (XAIR) is -4.01.